The Jackson Laboratory completed its acquisition of the New York Stem Cell Foundation and held a launch event at NYSCF’s Manhattan campus to mark a unified nonprofit research organization. The merger pairs JAX’s genetics and mouse‑model expertise with NYSCF’s stem‑cell automation and translational platforms. Leaders said the combined entity aims to accelerate translational research and scale bespoke gene and cell therapies; cited examples include rapid custom gene‑therapy timelines for rare disease patients. Speakers included JAX CEO Lon Cardon and former NIH director Francis Collins, who highlighted the collaboration’s potential to bridge genetics and human stem‑cell work at scale.